Primary Site >> Colorectal Cancer
Gene >> CYP2C9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. PMID: 11325819 Ref: Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. PMID: 11470765 |
Ref: Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. PMID: 11960920 Ref: A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. PMID: 12419832 |
Ref: P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing. PMID: 15856231 Ref: Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking, and risk of colorectal carcinoma in the Nurses' Health Study and the Physicians' Health Study. PMID: 15924351 Ref: A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. PMID: 16006997 Ref: No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma. PMID: 16141797 |
Ref: Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients. PMID: 16445595 Ref: Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. PMID: 16797247 |
Ref: The association of CYP2C9 gene polymorphisms with colorectal carcinoma in Han Chinese. PMID: 17368604 Ref: Combinations of cytochrome P450 gene polymorphisms enhancing the risk for sporadic colorectal cancer related to red meat consumption. PMID: 17627011 |
Ref: Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity. PMID: 17851638 Ref: Drug interactions between chemotherapeutic regimens and antiepileptics. PMID: 18803983 Ref: Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk. PMID: 18990750 |
Ref: No modification of the beneficial effect of NSAIDs on colorectal cancer by CYP2C9 genotype. PMID: 19581657 |
Ref: Cigarette smoking, genetic variants in carcinogen-metabolizing enzymes, and colorectal cancer risk. PMID: 20937634 |
Ref: Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk. PMID: 21317201 Ref: Modification of menopausal hormone therapy-associated colorectal cancer risk by polymorphisms in sex steroid signaling, metabolism and transport related genes. PMID: 21490239 |
Ref: Meta-analysis of cytochrome P-450 2C9 polymorphism and colorectal cancer risk. PMID: 23145098 Ref: Analysis of the Functional Polymorphism in the Cytochrome P450 CYP2C8 Gene rs11572080 with Regard to Colorectal Cancer Risk. PMID: 23420707 |
Ref: Quantitative assessment of the effect of cytochrome P450 2C9 gene polymorphism and colorectal cancer. PMID: 23577132 |
Ref: Association between cytochrome P450 2C9 gene polymorphisms and colorectal cancer susceptibility: evidence from 16 case-control studies. PMID: 24414392 Ref: Genetic variations in the xenobiotic-metabolizing enzymes CYP1A1, CYP1A2, CYP2C9, CYP2C19 and susceptibility to colorectal cancer among Turkish people. PMID: 24527758 Ref: Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: colon cancer family registry. PMID: 24677636 |
Ref: Elevated prothrombin time/international normalized ratio associated with concurrent administration of regorafenib and warfarin in a patient with advanced colorectal cancer. PMID: 27398225 |
Ref: Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). PMID: 28817838 |